Antibiotic Treatment Guidelines for Gonorrhea
Introduction to Gonorrhea Treatment
- Most patients who report penicillin allergy are not truly allergic when tested, according to the Centers for Disease Control and Prevention (CDC) 1
Alternative Treatment Options
- Spectinomycin 2g IM in a single dose (where available) is a recommended alternative treatment, as suggested by the CDC 2
- The first-line treatment for uncomplicated gonorrhea is a single intramuscular dose of ceftriaxone 250 mg plus azithromycin 1 g orally in a single dose, addressing both gonorrhea infection and possible co-infection with Chlamydia trachomatis while helping to prevent antimicrobial resistance, as recommended by the CDC 3
Treatment Regimens
- Uncomplicated gonorrhea can be treated with ceftriaxone 250 mg IM as a single dose plus azithromycin 1 g orally as a single dose, with test-of-cure in 1 week required for alternative regimens such as cefixime 400 mg orally in a single dose plus azithromycin 1 g orally in a single dose, as recommended by the CDC 3
- Severe cephalosporin allergy can be treated with azithromycin 2 g orally in a single dose, with test-of-cure in 1 week required, as recommended by the CDC 3
- Pregnant women should receive ceftriaxone 250 mg IM plus azithromycin 1 g orally, and should not receive quinolones or tetracyclines, as recommended by the American College of Obstetricians and Gynecologists and the CDC 3, 4, 5, 2
- Patients with HIV should receive the same treatment regimen as HIV-negative patients, as recommended by the CDC 4, 3, 5, 2
Special Considerations
- Pharyngeal infections require ceftriaxone-based therapy as they are more difficult to eradicate, according to the CDC 3
- Uncomplicated urogenital and rectal infections can be treated with the standard regimen of ceftriaxone 250 mg IM plus azithromycin 1 g orally in a single dose, as recommended by the CDC 3
- Patients with gonorrhea and pelvic inflammatory disease (PID) should receive ceftriaxone, doxycycline, and metronidazole 500 mg orally twice daily for 14 days, as recommended by the American College of Obstetricians and Gynecologists 5, 2
Evolution of Treatment Guidelines
| Year | Recommended Treatment |
|---|---|
| 1993 | ceftriaxone 125 mg IM, cefixime 400 mg orally, ciprofloxacin 500 mg orally, or ofloxacin 400 mg orally |
| 2006 | ceftriaxone 250 mg IM, plus doxycycline 100 mg orally twice daily for 14 days |
| Current | ceftriaxone 250 mg IM, plus azithromycin 1 g orally as a single dose |
Discontinued Treatments
- Fluoroquinolones, such as ciprofloxacin and ofloxacin, are no longer recommended due to widespread resistance, as stated by the Infectious Diseases Society of America and the CDC 6, 3
- Oral cephalosporins like cefixime are no longer first-line due to increasing minimum inhibitory concentrations (MICs), according to the CDC 3
Follow-up and Partner Treatment
- Test-of-cure is not needed for uncomplicated urogenital or rectal gonorrhea treated with the recommended regimen, but retesting is recommended 3 months after treatment due to high reinfection rates, as advised by the CDC 3
- Sexual partners from the past 60 days should be identified and treated with the same treatment regimen as the index case, including coverage for chlamydia due to high co-infection rates, as recommended by the CDC 3, 2, 4
- Partners should be instructed to abstain from sexual activity until both they and the index patient have completed treatment and are asymptomatic, and should be screened for other STIs including syphilis and HIV, as recommended by the CDC 2, 4, 3, 5
Common Pitfalls
- Inadequate pharyngeal treatment, neglecting partner treatment, missing co-infections, and using outdated treatments are common pitfalls that can lead to treatment failure or reinfection, as highlighted by the CDC and the Infectious Diseases Society of America 3, 6
- Forgetting to consider alternative treatments, such as spectinomycin 2 g IM in a single dose or other injectable cephalosporins, is also a common mistake, as reported by the CDC and other authorities 2, 4, 3, 5
- Not advising patients to return for retesting in 3 months due to high reinfection rates is another common mistake, as recommended by the CDC 2, 4, 3, 5